SMARCB1 and cancer: These reports demonstrate potential efficacy beyond SNSCC, encompassing cases responding after fulminant irAEs [10], SMARCB1‐deficient cancer achieving CRs [27], and even successful CRs with neoadjuvant tislelizumab [28].